← SynDRA
DIFLUPREDNATE
SynDRA canonical compound SYN0023602 — structure-anchored drug synonym record
| Clinical phase | Launched |
|---|
| Approval status | Approved · Rx/OTC |
|---|
| Primary target(s) | NR3C1 |
|---|
| Mechanism of action | glucocorticoid receptor agonist |
|---|
| Indication | endogenous uveitis |
|---|
| Disease area | ophthalmology |
|---|
All known targets
Mechanisms of action (all sources)
- NR3C1 AGONIST
- ANXA1 AGONIST
Bioactivity evidence (ChEMBL activities table — not curator-asserted)
- APEX1
- ATXN2
- GLS
- GMNN
- HDAC6
- HIF1A
- IDH1
- LMNA
- NPSR1
- TDP1
Screening evidence (raw PubChem HTS — uncurated, known false-positive rate)
- ANDR
- CFTR
- IL1B
- SC5A7
- SMCA2
Drug classes
ATC classes
- D07A · CORTICOSTEROIDS, PLAIN
- S01B · ANTIINFLAMMATORY AGENTS
Cross-references
Synonyms
- DUREZOL
- Durezol
- durezol
- Difluprednato
- W-6309
- Durezol (TN)
- DFBA
- Myser
- Epitopic
- Difluoroprednisolone butyrate acetate
- CM 9155
- S8A06QG2QE
- Difluprednatum
- MLS000028663
- MLS001148580
- CHEBI:31485
- SMR000058924
- 6ALPHA,9ALPHA-DIFLUOROPREDNISOLONE 21-ACETATE 17-BUTYRATE
- UNII-S8A06QG2QE
- Difluprednatum [INN-Latin]
- Difluprednato [INN-Spanish]
- Difluprednate [USAN:INN:JAN]
- NCGC00168749-01
- EINECS 245-815-4
- MFCD00214273
- Opera_ID_1287
- DIFLUPREDNATE [MI]
- DIFLUPREDNATE [INN]
- DIFLUPREDNATE [JAN]
- SCHEMBL4580
- DIFLUPREDNATE [USAN]
- DIFLUPREDNATE [VANDF]
- MLS001333701
- st60-1
- DIFLUPREDNATE [MART.]
- DIFLUPREDNATE [WHO-DD]
- GTPL7474
Reported adverse events
Look up DIFLUPREDNATE in the interactive SynDRA portal →